Fakultní nemocnice Ostrava

Ostrava 70852

1 studies enrolling now · 11 studies all time

What they study most

Acute Myeloid Leukemia, Aneurysmal Subarachnoid Hemorrhage, Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Leukemia, Leukemia, Myelomonocytic, Chronic, Macular Edema Secondary to Retinal Vein Occlusion, Multiple Myeloma, Myelodysplastic Syndromes, Neovascular Age-Related Macular Degeneration

Studies at this site

• A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer — Recruiting now
• CRF2 Agonist for the Treatment of Worsening Heart Failure — Paused
• A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) — Completed
• Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye — Completed
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression — Completed
• Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs — Completed
• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) — Completed
• ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients — Completed
• Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM — Stopped early
• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth — Completed
• Clazosentan in Aneurysmal Subarachnoid Hemorrhage — Stopped early